CRISPR/Cas9: A powerful genome editing technique for the treatment of cancer cells with present challenges and future directions
Abu Hazafa,Muhammad Mumtaz,Muhammad Fras Farooq,Shahid Bilal,Sundas Nasir Chaudhry,Musfira Firdous,Huma Naeem,Muhammad Obaid Ullah,Muhammad Yameen,Muhammad Shahid Mukhtiar,Fatima Zafar
DOI: https://doi.org/10.1016/j.lfs.2020.118525
IF: 6.78
2020-12-01
Life Sciences
Abstract:<p>Cancer is one of the most leading causes of death and a major public health problem, universally. According to accumulated data, every year, approximately 8.5 million people died because of the lethality of cancer. Recently, a new RNA domain-containing endonuclease-based genome engineering technology, namely the clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein-9 (Cas9) have been proved as a powerful technique in the treatment of cancer due to its multifunctional properties including high specificity, accuracy, time reducing and cost-effective strategies with minimum off-target effects. The present review investigates the overview of recent studies on the newly developed genome-editing strategy, CRISPR/Cas9, as an excellent pre-clinical therapeutic option in the reduction and identification of new tumor target genes in the solid tumors. Based on accumulated data, we revealed that CRISPR/Cas9 significantly inhibited the robust tumor cell growth (breast, lung, liver, colorectal, and prostate) by targeting the oncogenes, tumor-suppressive genes, genes associated to therapies by inhibitors, and genes associated to chemotherapies drug resistance, and suggested that CRISPR/Cas9 could be a potential therapeutic target in inhibiting the tumor cell growth by suppressing the cell-proliferation, metastasis, invasion and inducing the apoptosis during the treatment of malignancies in the near future. The present review also discussed the current challenges, and barriers and proposed future recommendations for a better understanding.</p>
biology